You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A daily client check-in system for outpatient substance abuse treatment

    SBC: COG ANALYTICS, LLC            Topic: NIDA

    Abstract Alcohol and illicit drug use remain highly prevalent in the US, and epidemiological surveillance surveys estimate that over 20.6 million individuals (~ 8% of the US population) meet standard diagnostic thresholds for substance use disorders (SAMHSA, 2011). Outpatient substance abuse treatment is the predominate method of treatment in the US for SUDs, typically involving intermittent cont ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. AN EXPANDED GENETIC INFORMATION SYSTEM

    SBC: ERAGEN BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The DNA alphabet is not limited to the four standard nucleotides. Rather, twelve nucleobases forming six base pairs joined by mutually exclusive hydrogen bonding patterns are possible within the geometry of the Watson-Crick base pair. These form An Expanded Genetic Information System (Aegis), a new, "rule based" molecular recognition system that carries protein ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  3. ASSAYS FOR ROS-INDUCED DNA DAMAGE

    SBC: ZEPTOMETRIX CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant):This project is a collaboration between ZeptoMetrix Corporation and Roswell Park Cancer Institute. The objective is to develop sensitive, quantitative and facile assays for measuring DNA damage caused by reactive oxygen species (ROS). ROS have been implicated in aging, cancer and several neurological diseases. Seven ROS-induced DNA lesions will be assayed, namel ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  4. CHROMOGENIC HER-2/NEU GENE AMPLIFICATION ASSAY

    SBC: NANOPROBES INC            Topic: N/A

    Overexpression of the Her-2/neu protein and amplification of the Her-2/neu gene are are the most widely accepted prognostic indicator of aggressive malignant behavior of invasive breast carcinoma. Accurate detection of Her-2/neu overexpression is critical in identifying patients suitable for serotherapy with humanized monoclonal antibody (Herceptin). Fluorescence in situ hybridization (FISH) has b ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  5. Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery

    SBC: IGI TECHNOLOGIES, INC            Topic: NCI

    DESCRIPTION (provided by applicant): The overall objective of the proposed research is to fully develop and conduct clinical translation of a novel technology that provides minimally invasive surgeons an ability to visualize exposed organ surfaces as wellas structures hidden by them, together with a true appreciation of depth. A long-standing need in minimally invasive laparoscopic surgery has bee ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. COATING FOR IMPROVED SENSITIVITY AND RANGE OF MICROARRAY

    SBC: STS BIOPOLYMERS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): An important development in medicine has been the ability to quickly and reliably screen individuals for diseases and more recently genetic markers which may pre-dispose individuals to develop illnesses during their lifetime. The development of clinical diagnostics based on gene expression profiles is approaching maturation due to ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. DETECTION OF PRION PROTEIN IN BLOOD

    SBC: SERACARE LIFE SCIENCES, INC.            Topic: N/A

    Prion diseases are 100 percent fatal, there is no treatment available, and cannot be diagnosed prior to the occurrence of symptoms. There is a public health need and an enormous market for a screening test that can help protect the blood supply, screen live animals, and ensure food safety. We propose to develop and validate an innovative, highly sensitive screening method for the detection of the ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a Nrf2 activator for the treatment of COPD

    SBC: CUREVEDA, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. In the US alone, the disease afflicts ~13 million people and is the third-leading cause of death. Cigarette smoking isthe primary risk factor for COPD, initiating a persistent and progressive inflammatory immune response. Respiratory infections and pollutants can ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a Nrf2 activator for the treatment of scleroderma

    SBC: CUREVEDA, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government